KR100517090B1 - 서방형 제약 조성물 및 제약 활성제의 방출 방법 - Google Patents

서방형 제약 조성물 및 제약 활성제의 방출 방법 Download PDF

Info

Publication number
KR100517090B1
KR100517090B1 KR10-2001-7004708A KR20017004708A KR100517090B1 KR 100517090 B1 KR100517090 B1 KR 100517090B1 KR 20017004708 A KR20017004708 A KR 20017004708A KR 100517090 B1 KR100517090 B1 KR 100517090B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
hydrophilic polymer
weight
nonionic hydrophilic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-2001-7004708A
Other languages
English (en)
Korean (ko)
Other versions
KR20010080156A (ko
Inventor
라젠 샤
아룬 피. 파텔
로이 티. 산드리
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100517090(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20010080156A publication Critical patent/KR20010080156A/ko
Application granted granted Critical
Publication of KR100517090B1 publication Critical patent/KR100517090B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR10-2001-7004708A 1998-10-14 1999-10-12 서방형 제약 조성물 및 제약 활성제의 방출 방법 Expired - Lifetime KR100517090B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14
US09/172,491 1998-10-14

Publications (2)

Publication Number Publication Date
KR20010080156A KR20010080156A (ko) 2001-08-22
KR100517090B1 true KR100517090B1 (ko) 2005-09-27

Family

ID=22627919

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-7004708A Expired - Lifetime KR100517090B1 (ko) 1998-10-14 1999-10-12 서방형 제약 조성물 및 제약 활성제의 방출 방법

Country Status (30)

Country Link
EP (1) EP1121116B1 (cg-RX-API-DMAC10.html)
JP (2) JP2002527388A (cg-RX-API-DMAC10.html)
KR (1) KR100517090B1 (cg-RX-API-DMAC10.html)
CN (1) CN1196481C (cg-RX-API-DMAC10.html)
AR (2) AR020780A1 (cg-RX-API-DMAC10.html)
AT (1) ATE382345T1 (cg-RX-API-DMAC10.html)
AU (1) AU765475B2 (cg-RX-API-DMAC10.html)
BR (1) BR9911648A (cg-RX-API-DMAC10.html)
CA (1) CA2346868C (cg-RX-API-DMAC10.html)
CO (1) CO5140079A1 (cg-RX-API-DMAC10.html)
CY (1) CY1107874T1 (cg-RX-API-DMAC10.html)
DE (1) DE69937891T2 (cg-RX-API-DMAC10.html)
DK (1) DK1121116T3 (cg-RX-API-DMAC10.html)
ES (1) ES2297936T3 (cg-RX-API-DMAC10.html)
HK (1) HK1040920B (cg-RX-API-DMAC10.html)
HU (1) HUP0104268A3 (cg-RX-API-DMAC10.html)
ID (1) ID29350A (cg-RX-API-DMAC10.html)
IL (2) IL142375A0 (cg-RX-API-DMAC10.html)
MY (1) MY121105A (cg-RX-API-DMAC10.html)
NO (1) NO327285B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ511010A (cg-RX-API-DMAC10.html)
PE (1) PE20001110A1 (cg-RX-API-DMAC10.html)
PL (1) PL198850B1 (cg-RX-API-DMAC10.html)
PT (1) PT1121116E (cg-RX-API-DMAC10.html)
RU (1) RU2259826C2 (cg-RX-API-DMAC10.html)
SK (2) SK286595B6 (cg-RX-API-DMAC10.html)
TR (1) TR200101088T2 (cg-RX-API-DMAC10.html)
TW (1) TW577738B (cg-RX-API-DMAC10.html)
WO (1) WO2000021525A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200103001B (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
DE60041281D1 (de) 2000-06-09 2009-02-12 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
CA2426666A1 (en) * 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
AU2003262059A1 (en) * 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
WO2004093883A2 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007016757A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
JP2009527577A (ja) * 2006-02-24 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム医薬組成物
RU2342144C1 (ru) * 2007-04-05 2008-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав, обладающий противосудорожным и психотропным действием
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
AU2014205356A1 (en) * 2013-01-09 2015-07-30 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
TWI869410B (zh) * 2019-06-10 2025-01-11 愛爾蘭商龐賽德萊昂健康公司 α-酮戊二酸鹽之持續釋放組合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015264A1 (en) * 1996-10-08 1998-04-16 Astra Aktiebolag PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DK0814782T3 (da) * 1995-12-22 2002-12-16 Nissan Chemical Ind Ltd Farmaceutisk præparat stabiliseret med et basisk middel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015264A1 (en) * 1996-10-08 1998-04-16 Astra Aktiebolag PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN

Also Published As

Publication number Publication date
EP1121116A2 (en) 2001-08-08
ATE382345T1 (de) 2008-01-15
DE69937891D1 (de) 2008-02-14
DE69937891T2 (de) 2008-12-11
NZ511010A (en) 2003-10-31
KR20010080156A (ko) 2001-08-22
TR200101088T2 (tr) 2001-10-22
SK5092001A3 (en) 2001-09-11
AU765475B2 (en) 2003-09-18
JP2002527388A (ja) 2002-08-27
CN1328454A (zh) 2001-12-26
SK286595B6 (sk) 2009-01-07
ES2297936T3 (es) 2008-05-01
AR069281A2 (es) 2010-01-13
EP1121116B1 (en) 2008-01-02
PL198850B1 (pl) 2008-07-31
SK286596B6 (sk) 2009-01-07
HK1040920A1 (en) 2002-06-28
HK1040920B (zh) 2005-07-29
IL142375A (en) 2012-01-31
NO327285B1 (no) 2009-06-02
PL348109A1 (en) 2002-05-06
BR9911648A (pt) 2001-03-20
PT1121116E (pt) 2008-03-12
DK1121116T3 (da) 2008-05-13
JP2006298945A (ja) 2006-11-02
AU6090999A (en) 2000-05-01
IL142375A0 (en) 2002-03-10
JP4938383B2 (ja) 2012-05-23
CA2346868C (en) 2008-09-09
WO2000021525A3 (en) 2000-08-10
ZA200103001B (en) 2002-07-11
PE20001110A1 (es) 2000-11-01
CA2346868A1 (en) 2000-04-20
RU2259826C2 (ru) 2005-09-10
TW577738B (en) 2004-03-01
AR020780A1 (es) 2002-05-29
HUP0104268A3 (en) 2002-06-28
NO20011695L (no) 2001-05-30
NO20011695D0 (no) 2001-04-04
CN1196481C (zh) 2005-04-13
WO2000021525A2 (en) 2000-04-20
MY121105A (en) 2005-12-30
CY1107874T1 (el) 2013-06-19
HUP0104268A2 (hu) 2002-04-29
CO5140079A1 (es) 2002-03-22
ID29350A (id) 2001-08-23

Similar Documents

Publication Publication Date Title
KR20010080156A (ko) 서방형 제약 조성물 및 제약 활성제의 방출 방법
JP2022190161A (ja) グルコキナーゼ活性化剤およびビグアナイド系血糖降下薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用
US6106864A (en) Pharmaceutical formulations containing darifenacin
US5681582A (en) Extended release, film-coated tablet of astemizole and pseudoephedrine
US20100311802A1 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
AU750617B2 (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
US20090017114A1 (en) Tranexamic acid formulations with reduced adverse effects
US20050192259A1 (en) Aldosterone antagonist compositions for release during aldosterone acrophase
HK1259458A1 (zh) 用於治疗心血管疾病的吉卡宾组合
CN1607947A (zh) 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物
US20030104054A1 (en) Delayed release anti-neoplastic product, use and formulation thereof
US20030147953A1 (en) Delayed release anti-fungal product, use and formulation thereof
KR20060118507A (ko) 유기 화합물을 포함하는 조성물
EP1784161B1 (en) Controlled-release formulation comprising tamsulosin hydrochloride
CN101043876A (zh) 包含可压性差的活性剂和生育酚聚乙二醇琥珀酸酯(tpgs)的片剂
MXPA01003731A (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
HK1068539B (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010413

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20020719

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20041026

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20050623

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20050916

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20050920

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20080911

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20090910

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20100910

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20110811

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20120821

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20120821

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20130820

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20130820

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20140825

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20140825

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20150819

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20150819

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20160818

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20180903

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20180903

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20200412

Termination category: Expiration of duration